XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended June 30, 2025Three Months Ended June 30, 2024
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $1,059 $1,059 $— $988 $988 
Other— 324 324 — 306 306 
Total— 1,383 1,383 — 1,294 1,294 
Nutritional Products —    
Pediatric Nutritionals587 467 1,054 564 495 1,059 
Adult Nutritionals370 788 1,158 369 722 1,091 
Total957 1,255 2,212 933 1,217 2,150 
Diagnostic Products —     
Core Laboratory351 1,007 1,358 327 1,002 1,329 
Molecular35 88 123 33 94 127 
Point of Care104 44 148 107 49 156 
Rapid Diagnostics321 223 544 345 238 583 
Total811 1,362 2,173 812 1,383 2,195 
Medical Devices —    
Rhythm Management340 333 673 292 315 607 
Electrophysiology322 378 700 287 340 627 
Heart Failure282 86 368 244 77 321 
Vascular283 474 757 275 449 724 
Structural Heart289 347 636 258 306 564 
Neuromodulation193 61 254 192 51 243 
Diabetes Care 794 1,187 1,981 637 1,011 1,648 
Total2,503 2,866 5,369 2,185 2,549 4,734 
Other5 — 5 4 — 4 
Total$4,276 $6,866 $11,142 $3,934 $6,443 $10,377 
Six Months Ended June 30, 2025Six Months Ended June 30, 2024
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,024 $2,024 $— $1,916 $1,916 
Other— 619 619 — 604 604 
Total— 2,643 2,643 — 2,520 2,520 
Nutritional Products —
Pediatric Nutritionals1,175 920 2,095 1,078 990 2,068 
Adult Nutritionals737 1,526 2,263 733 1,417 2,150 
Total1,912 2,446 4,358 1,811 2,407 4,218 
Diagnostic Products —
Core Laboratory683 1,852 2,535 637 1,897 2,534 
Molecular75 170 245 75 181 256 
Point of Care204 86 290 205 90 295 
Rapid Diagnostics720 437 1,157 826 498 1,324 
Total1,682 2,545 4,227 1,743 2,666 4,409 
Medical Devices —
Rhythm Management644 614 1,258 563 606 1,169 
Electrophysiology621 708 1,329 556 658 1,214 
Heart Failure544 163 707 481 145 626 
Vascular551 916 1,467 529 884 1,413 
Structural Heart571 642 1,213 491 588 1,079 
Neuromodulation369 113 482 373 96 469 
Diabetes Care1,542 2,266 3,808 1,226 1,991 3,217 
Total4,842 5,422 10,264 4,219 4,968 9,187 
Other8 — 8 7 — 7 
Total$8,444 $13,056 $21,500 $7,780 $12,561 $20,341 

Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the second quarter of 2025 and 2024, COVID-19 testing-related sales totaled $55 million and $102 million, respectively. In the first six months of 2025 and 2024, Abbott’s COVID-19 testing-related sales totaled $139 million and $306 million, respectively.
Remaining Performance Obligations

As of June 30, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $5.9 billion in the Diagnostic Products segment and $427 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 53 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2024$568 
Unearned revenue from cash received during the period252 
Revenue recognized related to contract liability balance(192)
Balance at June 30, 2025$628